We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Salivary excretion of systemically injected [<sup>18</sup>F]DCFPyL in prostate cancer patients undergoing PSMA scans.
- Authors
Fernandes, Bruna; Roy, Jyoti; Basuli, Falguni; Warner, Blake M.; Lindenberg, Liza; Mena, Esther; Adler, Steven S.; Griffiths, Gary L.; Choyke, Peter L.; Lin, Frank I.
- Abstract
Introduction: Prostate-specific membrane antigen (PSMA) is present in high amounts in salivary glands, but it is unclear whether labeled binders of PSMA are excreted in the saliva. Methods: Ten patients with prostate cancer underwent whole-body [18F]DCFPyL PET/CT (NCT03181867), and saliva samples were collected between 0-120 minutes post-injection. [18F]DCFPyL salivary excretion was measured over 120 minutes and expressed as %ID/g. Protein-associated binding was estimated by the percentage of [18F]DCFPyL versus parent radiotracer. Results: All PET scans of 10 patients (69 ± 8 years) with histologically confirmed prostate cancer (PSA= 2.4 ± 2.4, and Gleason Grade = 6-9) showed high uptake of [18F]-DCFPyL in salivary glands while 8 patients demonstrated high uptake in the saliva at 45 minutes. The intact [18F]-DCFPyL (98%) was also confirmed in the saliva samples at 120 min with increasing salivary radioactivity between 30-120 min. Conclusion: Systemically injected [18F]DCFPyL shows salivary gland uptake, an increasing amount of which is secreted in saliva over time and is not maximized by 120 minutes post-injection. Although probably insignificant for diagnostic studies, patients undergoing PSMA-targeted therapies should be aware of radioactivity in saliva.
- Subjects
PROSTATE cancer patients; PROSTATE-specific membrane antigen; EXCRETION; SALIVARY glands; POSITRON emission tomography
- Publication
Frontiers in Oncology, 2024, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2024.1367962